Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 19 Lung Neoplasms 5 Small Cell Lung Carcinoma 4 Ovarian Neoplasms 4 Neoplasms 4 Colorectal Neoplasms 4 Uterine Cervical Neoplasms 3 Urinary Bladder Neoplasms 3 Squamous Cell Carcinoma of Head and Neck 3 Recurrence 3 Pancreatic Neoplasms 3 Neoplasm Metastasis 3 Multiple Myeloma 3 Lymphoma, Large B-Cell, Diffuse 3 Breast Neoplasms 3 Vulvar Neoplasms 2 Vaginal Neoplasms 2 Triple Negative Breast Neoplasms 2 Prostatic Neoplasms 2 Lymphoma, Non-Hodgkin 2 Head and Neck Neoplasms 2 Cholangiocarcinoma 2 Carcinoma, Transitional Cell 2 Carcinoma, Hepatocellular 2 Urothelial Cancer 1 Urinary Bladder Diseases 1 Thyroid Neoplasms 1 Thyroid Cancer, Papillary 1 Thrombocytosis 1 Testicular Neoplasms 1

Interventions

tremelimumab 1 durvalumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Muscle-invasive Bladder Cancer × durvalumab × Clear all

NCT03234153 2020-06-17

NITIMIB

Insel Gruppe AG, University Hospital Bern

Phase 2 Terminated

Muscle-invasive Bladder Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡